Literature DB >> 12101070

Osteoprotegerin and inflammation.

N Saidenberg Kermanac'h1, Natacha Bessis, M Cohen-Solal, M C De Vernejoul, Marie-Christophe Boissier.   

Abstract

RANK, RANKL, and OPG have well established regulatory effects on bone metabolism. RANK is expressed at very high levels on osteoclastic precursors and on mature osteoclasts, and is required for differentiation and activation of the osteoclast. The ligand, RANKL binds to its receptor RANK to induce bone resorption. RANKL is a transmembrane protein expressed in various cells type and particularly on osteoblast and activated T cells. RANKL can be cleaved and the soluble form is active. Osteoprotegerin decoy receptor (OPG), a member of the TNF receptor family expressed by osteoblasts, strongly inhibits bone resorption by binding with high affinity to its ligand RANKL, thereby preventing RANKL from engaging its receptor RANK. This system is regulated by the calciotropic hormones. Conversely, the effects of RANKL, RANK, and OPG on inflammatory processes, most notably on the bone resorption associated with inflammation, remain to be defined. The RANK system seems to play a major role in modulating the immune system. Activated T cells express RANKL messenger RNA, and knock-out mice for RANKL acquire severe immunological abnormalities and osteopetrosis. RANKL secretion by activated T cells can induce osteoclastogenesis. These mechanisms are enhanced by cytokines such as TNF-alpha, IL-1, and IL-17, which promote both inflammation and bone resorption. Conversely, this system is blocked by OPG, IL-4, and IL-10, which inhibit both inflammation and osteoclastogenesis. These data may explain part of the abnormal phenomena in diseases such as rheumatoid arthritis characterized by both inflammation and destruction. Activated T cells within the rheumatoid synovium express RANKL. Synovial cells are capable of differentiating to osteoclast-like cells under some conditions, including culturing with M-CSF and RANKL. This suggests that the bone erosion seen in rheumatoid arthritis may result from RANKL/RANK system activation by activated T cells. This opens up the possibility that OPG may have therapeutic effects mediated by blockade of the RANKL/RANK system.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12101070

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  15 in total

1.  Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis.

Authors:  Nathalie Saidenberg-Kermanac'h; Natacha Bessis; Delphine Lemeiter; Marie-Christine de Vernejoul; Marie-Christophe Boissier; Martine Cohen-Solal
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

Review 2.  Theories concerning the pathogenesis of the acute charcot foot suggest future therapy.

Authors:  William J Jeffcoate
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810

3.  Soluble RANKL Cleaved from Activated Lymphocytes by TNF-α-Converting Enzyme Contributes to Osteoclastogenesis in Periodontitis.

Authors:  Hiroyuki Kanzaki; Seicho Makihira; Maiko Suzuki; Takenobu Ishii; Alexandru Movila; Josefine Hirschfeld; Hani Mawardi; Xiaoping Lin; Xiaozhe Han; Martin A Taubman; Toshihisa Kawai
Journal:  J Immunol       Date:  2016-10-07       Impact factor: 5.422

4.  Development of Biomarker Models to Predict Outcomes in Lupus Nephritis.

Authors:  Bethany J Wolf; John C Spainhour; John M Arthur; Michael G Janech; Michelle Petri; Jim C Oates
Journal:  Arthritis Rheumatol       Date:  2016-08       Impact factor: 10.995

5.  Relationship between bone mineral density and urine level of NTx in rheumatoid arthritis.

Authors:  Tohgo Nonaka; Fumiaki Nishisaka; Kanji Fukuda; Satoshi Sohen; Chiaki Hamanishi
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

Review 6.  An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases.

Authors:  Eduardo Maldonado-Gonzales; Peter Pietschmann
Journal:  Wien Med Wochenschr       Date:  2010-08-16

7.  Fibronectin has multifunctional roles in posterior capsular opacification (PCO).

Authors:  Mahbubul H Shihan; Mallika Kanwar; Yan Wang; Erin E Jackson; Adam P Faranda; Melinda K Duncan
Journal:  Matrix Biol       Date:  2020-03-12       Impact factor: 11.583

8.  Effects of erythropoietin on osteoblast proliferation and function.

Authors:  Lvhua Guo; Tao Luo; Ying Fang; Lan Yang; Liping Wang; Jingwen Liu; Bin Shi
Journal:  Clin Exp Med       Date:  2012-11-08       Impact factor: 3.984

9.  Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients.

Authors:  N Franchimont; C Reenaers; C Lambert; J Belaiche; V Bours; M Malaise; P Delvenne; E Louis
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

10.  The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy.

Authors:  Agbor Ndip; Alfred Williams; Edward B Jude; Ferdinand Serracino-Inglott; Steve Richardson; J V Smyth; Andrew J M Boulton; M Yvonne Alexander
Journal:  Diabetes       Date:  2011-06-09       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.